Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
Overview
- Phase
- Early Phase 1
- Intervention
- 18F-T807
- Conditions
- Neurodegenerative Disorders
- Sponsor
- First Affiliated Hospital of Fujian Medical University
- Enrollment
- 50
- Locations
- 1
- Primary Endpoint
- standardized uptake value ratio (SUVR)
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
Alzheimer's disease, Parkinson's disease, and Huntington's disease are common neurodegenerative diseases. Tau is a microtubule-associated protein, and aggregated tau resulting from hyperphosphorylation is a pathological feature of a group of neurodegenerative diseases known as tauopathies. The 18F-T807 (AV1451) molecular probe is a novel molecularly targeted imaging agent that exhibits high affinity and good selectivity for tau.
Detailed Description
In this study, 18F-T807 (AV1451) molecular probe PET/CT was used to monitor the regional distribution and the degree of deposition in patients with neurodegenerative diseases, and compared with clinical symptoms to evaluate its value in the early differential diagnosis of neurodegenerative diseases.
Investigators
Shaobo Yao, PhD
Director of Nuclear Medicine Department
First Affiliated Hospital of Fujian Medical University
Eligibility Criteria
Inclusion Criteria
- •Patients or their families complain of significant memory impairment;
- •Objective memory impairment (e.g., tests of article identification, recall, delayed memory);
- •Be able to obtain complete diagnosis and treatment records and be able to carry out long-term follow-up;
- •Signed written consent.
Exclusion Criteria
- •Psychiatric disorders: including anxiety disorder, affective disorder, severe psychosis, or drug-induced psychosis;
- •Pregnancy or lactation.
Arms & Interventions
18F-T807, PET/CT
PET/CT perform after injecting 18F-T807
Intervention: 18F-T807
Outcomes
Primary Outcomes
standardized uptake value ratio (SUVR)
Time Frame: From right after tracer injection to 2-hours post-injection
the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference
Aβ42 in CSF
Time Frame: Within 2 hours prior to tracer injection
Aβ42 (amyloid beta isoform 42) is significantly lower in the cerebrospinal fluid of patients with neurodegenerative diseases and is one of the biomarkers used clinically to diagnose neurodegenerative diseases
t-tau in CSF
Time Frame: Within 2 hours prior to tracer injection
t-tau (total tau) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
NfL in the blood
Time Frame: Within 2 hours prior to tracer injection
NfL is significantly increased in the blood of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
NfL in CSF
Time Frame: Within 2 hours prior to tracer injection
NfL (neurofilament light chain) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration
p-tau in CSF
Time Frame: Within 2 hours prior to tracer injection
p-tau (tau phosphorylated at Thr-181) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration